ArticleProbiotics and antimicrobial proteins2026
Probiotic Properties of Pediococcus acidilactici Z123 and its Intervention Effects and Mechanisms on Hypercholesterolemia in Mice.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The intervention effects and underlying mechanisms of Lactobacillus strains against hypercholesterolemia in mice have been extensively documented. However, fewer studies have focused on the cholesterol-lowering potential and the corresponding metabolic regulatory mechanisms of Pediococcus acidilactici. In the present study, we first characterized the in vitro probiotic properties of a novel lactic acid bacterial strain, Pediococcus acidilactici Z123 (P. acidilactici Z123), which exhibited prominent cholesterol-lowering activity. Subsequently, intragastric administration of P. acidilactici Z123 was carried out in a mouse model of high-fat diet-induced hypercholesterolemia to assess its intervention effect and elucidate the underlying molecular mechanisms. The results revealed that P. acidilactici Z123 possessed desirable probiotic characteristics such as auto-aggregation, adhesion ability, and gastrointestinal fluid tolerance, and showed good biosafety, inculding antibiotic susceptibility and no hemolytic activity. In vivo results demonstrated that supplementation with P. acidilactici Z123 effectively alleviated excessive body weight gain and reduced visceral fat accumulation, improved serum lipid profiles, and ameliorated the histological morphology of the liver and epididymal adipose tissue. Untargeted metabolomics indicated that P. acidilactici Z123 exerted a significant regulatory effect on lipolysis in adipocytes, PPAR and AMPK signaling pathways, primary bile acid metabolism, bile secretion, tryptophan metabolism, etc. Notably, such metabolic regulation was further verified at the transcriptional level. Quantitative reverse transcription PCR (qRT-PCR) analysis revealed that P. acidilactici Z123 intervention could inhibit cholesterol synthesis by downregulating the expression of Hmgcr and Srebf1, and upregulating the expression of Prkaa1. Meanwhile, it also elevated the expression of genes related to fatty acid oxidation (Cpt1a, Pparα) and bile acid synthesis (Cyp7a1). The present findings will provide valuable theoretical evidence for the development and application of novel functional probiotic products with lipid-regulating properties.
Indexed as
Identifiers
42377780What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.